Vizual Stocks works best vertically on mobile.
VizualStocks APIOperating KPI and segment definitions available for Arcutis Biotherapeutics (ARQT) through the VizualStocks API.
Revenue recognized by Arcutis from licensing and collaboration arrangements, separate from ZORYVE product sales, including Sato and Huadong upfront or milestone consideration. Historical amounts also include noncash consideration under the Iolyx collaboration; this is recognized revenue rather than contract value or cash receipts.
otherRevenueNet revenue from Arcutis's ZORYVE (roflumilast) cream 0.05%, the lower-strength topical formulation launched in October 2025 for mild to moderate atopic dermatitis in children ages 2 to 5, after sales deductions.
zoryveCream005RevenueNet revenue from Arcutis's ZORYVE (roflumilast) cream 0.15%, a topical treatment for mild to moderate atopic dermatitis, after sales deductions. The series begins with its U.S. commercial launch in July 2024 and includes subsequent Canadian sales.
zoryveCream015RevenueNet revenue from Arcutis's ZORYVE (roflumilast) cream 0.3%, a topical treatment for plaque psoriasis, after sales deductions. This product disaggregation includes its U.S. and Canadian sales and retains the original cream-only scope before the other formulations launched.
zoryveCream03RevenueNet revenue from Arcutis's ZORYVE (roflumilast) topical foam 0.3%, after sales deductions. The formulation treats seborrheic dermatitis and, following its 2025 indication expansion, scalp and body plaque psoriasis; the series includes all disclosed foam sales.
zoryveFoamRevenue